Melanotan I vs Pentapeptide-18
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Afamelanotide, Scenesse
Melanotan I is the research name for afamelanotide (code CUV1647), a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), also written as [Nle4, D-Phe7]-alpha-MSH or NDP-MSH. Sold as Scenesse, it was approved by the EMA in 2014 and the FDA in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP), one of a few approved melanocortin drugs alongside bremelanotide (Vyleesi) and setmelanotide (Imcivree). The approval covers only the 16 mg bioresorbable implant placed under the skin by a clinician. The injectable 'Melanotan I' sold online is not approved for anything.
Also: Leuphasyl, Tyr-Ala-Gly-Phe-Leu
Pentapeptide-18 is Lipotec's Leuphasyl, a 'Botox-like' cosmetic peptide modeled on enkephalins, the body's own calming neuropeptides. It is mostly sold alongside Argireline, with the claim that the two relax expression lines better together. It is a cosmetic ingredient, and the evidence is small and mostly manufacturer-run.
Key Comparison Insights
- Melanotan I is FDA approved, while Pentapeptide-18 remains in research stages.
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- Melanotan I has stronger research evidence (FDA Approved) compared to Pentapeptide-18 (Limited Research).
Detailed Comparison
| Attribute | Melanotan I | Pentapeptide-18 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Afamelanotide binds and activates the melanocortin-1 receptor (MC1R) on pigment-producing melanocytes, driving production of eumelanin, the dark, photoprotective form of melanin. Two amino acid swaps from natural alpha-MSH - norleucine at position 4 and D-phenylalanine at position 7 - make it bind MC1R more tightly and resist breakdown, so it lasts far longer and acts more potently than the native hormone. The extra eumelanin absorbs and scatters light and also brings antioxidant and DNA-repair-supporting effects, which is why it raises the light dose EPP patients can tolerate before pain hits. Unlike Melanotan II, it is selective enough toward MC1R that it is not primarily a sexual-function or appetite agent. | Pentapeptide-18 is Tyr-Ala-Gly-Phe-Leu, a close copy of Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) with one amino acid swapped. The theory is that it binds enkephalin receptors on nerve endings, which dampens nerve activity and lowers acetylcholine release at the junction with facial muscles. Argireline works at a different step (the SNARE complex inside the nerve ending), which is why the two get marketed as a combo. The same big caveat as Argireline applies: it is sold on a nerve-to-muscle mechanism, but nobody has shown in living skin that a topical cream delivers enough peptide to the muscle to do this. |
| Common Dosing | 500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance) Daily during loading (1-2 weeks), then 1-2x weekly maintenance | About 2-5% of the commercial solution in a finished product Once or twice daily |
| Administration | Subcutaneous implant (not injection) | Topical (serums, creams) |
| Typical Duration | Long-term / as needed before sun season | 28 days to 2 months in studies; ongoing use to maintain any effect |
| Best Time to Take | Before the sunny season (approved implant); evening for unapproved injectables | Morning and/or evening, on clean skin |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the few peptides on this list with gold-standard human evidence. The pivotal data came from two multicenter, randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2015 (Langendonk et al., 373(1):48-59), enrolling 168 EPP patients across the EU (74) and US (94) who received the 16 mg implant or placebo every 60 days. Afamelanotide significantly increased pain-free time in sunlight (median 69.4 vs 40.8 hours in the US trial; 6.0 vs 0.8 hours in the EU trial, where phototoxic reactions also dropped from 146 to 77), and improved disease-specific quality of life, with mostly mild adverse events. Long-term observational follow-up of EPP patients has supported continued benefit and an acceptable safety profile. Clinuvel is also running a phase 3 vitiligo trial (CUV105), with topline results guided for December 2026. The big caveats: this approval is narrowly for EPP, not for cosmetic tanning, and the unregulated injectable 'Melanotan' products people buy online are not the same controlled, clinician-administered implant and carry real risks. Bottom line: a genuinely proven, approved drug for a rare condition, frequently misused outside that lane. | The most quoted numbers come from a Lipotec study: about 11% wrinkle reduction with 5% Leuphasyl alone over 28 days in a small panel, and about 25% with 5% Leuphasyl plus 5% Argireline. The company calls that synergy, but on its own figures the combination roughly equals the two effects added together, so 'synergistic' is a stretch. The one journal paper we found is Dragomirescu and colleagues (2014, Cosmetics, MDPI), which tested 0.5%, 1% and 2% emulsions around the eyebrows and eyes for efficacy and safety. Trade summaries say only the 2% cream gave a significant improvement after two months in about 20 volunteers; we could not read the full paper to confirm the numbers. A 2020 review of cosmetic peptides lists it among the neurotransmitter-inhibitor peptides and notes that much of the support comes from the manufacturer. Bottom line: safe enough as a skincare ingredient and plausible on paper, but expect subtle softening at most, not anything close to an injection. |
Frequently Asked Questions: Melanotan I vs Pentapeptide-18
What is the difference between Melanotan I and Pentapeptide-18?
Melanotan I is a skin & hair peptide that melanotan i is the research name for afamelanotide (code cuv1647), a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-msh), also written as [nle4, d-phe7]-alpha-msh or ndp-msh. sold as scenesse, it was approved by the ema in 2014 and the fda in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (epp), one of a few approved melanocortin drugs alongside bremelanotide (vyleesi) and setmelanotide (imcivree). the approval covers only the 16 mg bioresorbable implant placed under the skin by a clinician. the injectable 'melanotan i' sold online is not approved for anything. Pentapeptide-18 is a skin & hair peptide that pentapeptide-18 is lipotec's leuphasyl, a 'botox-like' cosmetic peptide modeled on enkephalins, the body's own calming neuropeptides. it is mostly sold alongside argireline, with the claim that the two relax expression lines better together. it is a cosmetic ingredient, and the evidence is small and mostly manufacturer-run. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Melanotan I or Pentapeptide-18?
Neither is universally "better" - the choice depends on your specific goals. Melanotan I is typically used for skin & hair purposes, while Pentapeptide-18 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Melanotan I and Pentapeptide-18 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Melanotan I and Pentapeptide-18 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.